SCHEMBL4886687

SCHEMBL4886687

O=Cc1ccc2cc(OCC(=O)O)ccc2c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN7 P35236 1/20 0.65
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
KDM4E B2RXH2 2/20 0.49
TDP1 Q9NUW8 1/20 0.49
ALOX15 P16050 2/20 0.47
TSHR P16473 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MCL1 Q07820 1/20 0.47
LMNA P02545 2/20 0.46
CA2 P00918 1/20 0.46
FFAR1 O14842 2/20 0.45
PPARG P37231 1/20 0.45
PPARD Q03181 1/20 0.45
PPARA Q07869 1/20 0.45
ALDH1A1 P00352 2/20 0.45
PDE2A O00408 1/20 0.45
PDE3B Q13370 1/20 0.45
PDE3A Q14432 1/20 0.45
P2RY12 Q9H244 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4076964 0.86 PTPN7 (0.85) PTPN7MEN1KMT2AKDM4ETDP1
SCHEMBL2608055 0.85 PTPN7 (0.63) PTPN7MEN1KMT2AKDM4ETDP1
SCHEMBL349060 0.84 ALOX15 (0.61) PTPN7MEN1KMT2AALOX15TSHR
SCHEMBL7336804 0.81 PTPN7 (0.58) PTPN7MEN1KMT2AKDM4ETDP1
SCHEMBL353914 0.81 MAOA (0.61) PTPN7TDP1ALOX15LMNAPPARG
SCHEMBL1250165 0.80 ALB (0.63) KMT2AFFAR1PPARGPPARDPPARA
SCHEMBL17094885 0.79 RAB9A (0.44) PTPN7MEN1KMT2ALMNAPPARA
SCHEMBL29367022 0.79 PTPN7 (1.00) PTPN7MEN1KMT2AKDM4ETDP1
SCHEMBL25640 0.79 PTPN7 (1.00) PTPN7MEN1KMT2AKDM4ETDP1
SCHEMBL20024689 0.78 ALOX15 (0.63) PTPN7MEN1KMT2AALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 US disclosed
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-24 US disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 WO disclosed
US-20080027094-A1 Tropane Compounds and Pharmaceutical Compositions Comprising the Same as an Active Ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-01-31 US disclosed
EP-1785421-A1 TROPAN COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2007-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS LRRK2, MYLK2, MYLK PTPN7 684/4885MEN1 1218/4885KMT2A 1345/4885
US-20080027094-A1 Tropane Compounds and Pharmaceutical Compositions Comprising the Same as an Active Ingredient CHRM1, CHRM3, CHRM2 PTPN7 2784/4885MEN1 2088/4885KMT2A 3966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.